Media Centre
Latest press releases
-
AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore
-
SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population
-
AstraZeneca completes equity investment agreement with Cellectis
-
Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
-
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.